Suchergebnisse - "Isakoff, S J"

PubPharm (24)

1

Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer : results from the NeoSTAR trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Spring, L. | Tolaney, S. | Fell, G. | +20

2

Antitumor activity of ipatasertib combined with chemotherapy : results from a phase Ib study in solid tumors

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Isakoff, S. | Tabernero, J. | Molife, L. | +18

3

FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Oliveira, M. | Saura, C. | Nuciforo, P. | +13

4

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : randomized phase II study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Han, H. | Diéras, V. | Robson, M. | +23

CommentIn: Ann Oncol. 2018 Jan 1;29(1):18-21. - PMID 29300815

5

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging (DOSI)

enthalten in: Cancer research | 2016

von Tromberg, B. | Zhang, Z. | Leproux, A. | +19

6

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging

enthalten in: Cancer research | 2016

von Tromberg, B. | Zhang, Z. | Leproux, A. | +19

7

Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

enthalten in: Annals of oncology | 2016

von Balmaña, J. | Cruz, C. | Arun, B. | +15

8

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Diéras, V. | Campone, M. | Yardley, D. | +10

9

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

enthalten in: Annals of oncology | 2015

von Diéras, V. | Campone, M. | Yardley, D. | +10

10

Bosutinib plus capecitabine for selected advanced solid tumours : results of a phase 1 dose-escalation study

enthalten in: British journal of cancer | 2014

von Isakoff, S. | Wang, D. | Campone, M. | +6